ライフサイエンスコーパス: Ebola

1 merging viral infections, such as dengue and Ebola.

2 Ebola, a hypervariable RNA virus causing fatalities of u

3 ve study of one ISG (CCDC92) that shows anti-Ebola activity in our screen reveals that CCDC92 can inh

4 ata of case counts to compare individuals in Ebola-affected health zones in DRC, April 2018-August 20

5 IAV and MERS-CoV along with the filoviruses Ebola and Marburg and two further coronaviruses, SARS-Co

6 Filoviruses such as Ebola and Marburg virus bud from the host membrane as en

7 noviocytes were permissive to infection with Ebola and Marburg viruses in vitro.

8 ruses, and the family Filoviridae, including Ebola and Marburg viruses, can cause severe disease and

9 We present structures of Ebola and Marburg VP40 matrix layers in intact virus-lik

10 s, including the viruses that cause measles, Ebola and rabies.

11 The Xpert Ebola and US Centers for Disease Control and Prevention

12 a popular solution that has been applied to Ebola and Zika virus disease outbreaks, among others, an

13 ase outbreaks such as SARS, MERS, Swine Flu, Ebola, and COVID-19 (on-going) have caused suffering, de

14 ) destroys enveloped viruses, including HIV, Ebola, and Zika virus, and remodels amyloid fibrils in s

15 n and replication strategies employed by the ebola- and marburgviruses, respectively.

16 e two of these new genera are similar to the ebola- and marburgviruses, the other two, discovered in

17 ms of the disease caused by the ebolaviruses Ebola, Bundibugyo, and Sudan are similar, and their area

18 expressing cells by infectious Zika virus or Ebola, Chikungunya, or eastern equine encephalitis pseud

19 ns for of cluster vaccination programs in an Ebola cluster outbreak response situation.

20 ting 95% accuracy for the detection of Zika, Ebola, dengue, chikungunya and yellow fever viruses in p

21 Filoviridae, including Ebola (EBOV) and Marburg (MARV) viruses, are emerging pa

22 tides of three different ebolavirus species, Ebola (EBOV), Sudan, and Reston viruses.

23 analysis estimates the relative risk of the Ebola endpoint occurring from after the blood draw throu

24 At an overall vaccine efficacy of 90%, 20 Ebola endpoints gave good power.

25 s, at an overall vaccine efficacy of 75%, 50 Ebola endpoints in the vaccinees provided good power.

26 The 2013-2016 West African Ebola epidemic has been the largest to date with >11 000

27 The 2013-2016 West African Ebola epidemic has been the largest to date with more th

28 The international response to the evolving Ebola epidemic in eastern Democratic Republic of Congo (

29 The 2014-2016 Ebola epidemic in West Africa provided an opportunity to

30 ublic health contingency planning for future Ebola epidemic, and help better allocate resources and e

31 The recent Ebola epidemics in West Africa underscore the great need

32 ublic health contingency planning for future Ebola epidemics, and help better allocate resources and

33 linical Research into Epidemic Response: The Ebola Experience.

34 Highly purified equine anti-Ebola F(ab')2 showed strong cross-neutralization of 2 Za

35 cination regimen and in response to in vitro Ebola glycoprotein stimulation of PBMCs isolated before

36 safe and provides specific immunity against Ebola glycoprotein, and is currently in phase 2 and 3 st

37 Ebola glycoprotein-induced activation of NK cells was de

38 locking cathepsin-mediated processing of the Ebola glycoprotein.

39 the activation and regulation of NK cells by Ebola glycoprotein.TRIAL REGISTRATIONClinicalTrials.gov

40 o a significant increase in the frequency of Ebola GP-specific CD4 and CD8 T cell responses.

41 lood samples from 70 patients with suspected Ebola hemorrhagic fever during a 2014 outbreak in Boende

42 omarkers for other infectious agents such as Ebola, HIV, and Zika.

43 The current outbreak of Ebola in eastern DR Congo, beginning in 2018, emerged in

44 uld be considered for individuals at risk of Ebola infection, who previously received the two-dose re

45 man immunodeficiency virus, tuberculosis, or Ebola, infectious diseases practitioners often interact

46 ection of human papilloma, vaccinia, dengue, Ebola, influenza A, human immunodeficiency, and hepatiti

47 For HIV, Ebola, influenza and numerous other viruses, envelope gl

48 otect against multiple pathogenic species of Ebola is not yet established, and eliciting durable resp

49 3, 32, 33, and 35 are superior inhibitors of Ebola (Mayinga) and Marburg (Angola) infectious viruses.

50 SARS, MERS, Ebola, Nipah and an array of arenavirus infections spora

51 s yielded successful antibody treatments for Ebola-one from genetically humanized mice and the other

52 tant in controlling infections by influenza, Ebola, or HIV-1 in animal models.

53 ct of clinical trials during the West Africa Ebola outbreak in 2014 highlighted many ethical challeng

54 d survivors and close contacts from the 1995 Ebola outbreak in Kikwit, Democratic Republic of Congo (

55 We also discuss the current Ebola outbreak in the Democratic Republic of the Congo a

56 The 2013-2016 Ebola outbreak in West Africa led to accelerated efforts

57 The West Africa Ebola outbreak was the largest outbreak ever recorded, w

58 ARS-CoV-2 outbreak, 2016 Zika pandemic, 2014 Ebola outbreak, 2001 anthrax letter attacks, and 1984 Ra

59 challenges for its implementation in a small Ebola outbreak.

60 patiotemporal dynamics of recent cholera and Ebola outbreaks and compare and contrast the spread of t

61 Ebola vaccine development efforts.IMPORTANCE Ebola outbreaks result in significant morbidity and mort

62 With the increasing frequency of Ebola outbreaks, it is crucial to identify the animal re

63 o implement clinical treatment trials during Ebola outbreaks, we should also focus on strengthening t

64 mportant to guide preventive measures during Ebola outbreaks.

65 underlying the neurologic manifestations in Ebola patients are not known.

66 HCWs feared managing Ebola patients, affecting their willingness to care for

67 les, respiratory syncytial virus, Nipah, and Ebola, possess an essential L-protein cofactor, required

68 valuated benefits and challenges of hospital Ebola preparation in developed countries.

69 E. dupreanum and R. madagascariensis and to Ebola-related filoviruses in P. rufus and R. madagascari

70 A range of post-Ebola sequelae have been reported in survivors, but litt

71 eded to provide protection against different Ebola species and to extend the durability of protection

72 ovement of the routine use of PPE as well as Ebola-specific PPE.

73 Ebola-specific T cell responses induced by vaccination a

74 driven networks (only temporal contacts) for Ebola spreading.

75 ith each of the 3 corresponding filoviruses (Ebola, Sudan, Marburg) or a heterologous contemporary li

76 zing longitudinal antibody repertoires of an Ebola survivor from disease onset.

77 -cell responses were significantly higher in Ebola survivors with post-Ebola syndrome.

78 vive the acute disease later experience post-Ebola syndrome, a constellation of symptoms whose causat

79 ficantly higher in Ebola survivors with post-Ebola syndrome.

80 -day interval and its relative impact on Rt, Ebola-targeted events corresponded to Rt of 1.52 (95% CI

81 ent events per health zone, categorized into Ebola-targeted or Ebola-untargeted, and into civilian-in

82 Ebola-targeted violence, primarily driven by civilian-in

83 rra Leone and note that a case definition of Ebola that is broader than those commonly applied may be

84 To evaluate the spatial dynamics of Ebola transmission and quantify the impact of vaccinatio

85 In 2015, the laboratory at the Ebola treatment center in Coyah, Guinea, confirmed Ebola

86 We observed 41 HCWs across 4 Ebola treatment centers in Georgia doffing PPE for simul

87 Violence targeting healthcare workers and Ebola treatment centers in the Democratic Republic of th

88 dy evaluated patients with EVD admitted to 5 Ebola treatment units (ETUs) in West Africa.

89 Ebola virus disease and were discharged from Ebola treatment units in Guinea.

90 Ebola virus disease who were discharged from Ebola treatment units.

91 lth zone, categorized into Ebola-targeted or Ebola-untargeted, and into civilian-induced, (para)milit

92 luate potential correlates of risk during an Ebola vaccination campaign in an outbreak.

93 a multivalent modified vaccinia Ankara (MVA) Ebola vaccine also appear promising and are progressing

94 yr (average, 29 yr) were vaccinated with the Ebola vaccine candidate chimpanzee adenovirus type 3-vec

95 Several Ebola vaccine candidates are available, but conducting r

96 of this approach as a potential addition to Ebola vaccine development efforts.IMPORTANCE Ebola outbr

97 Ebola vaccine development was accelerated in response to

98 Both heterologous and homologous Ad26,MVA Ebola vaccine regimens are well tolerated in healthy adu

99 ecombinant vesicular stomatitis virus (rVSV) Ebola vaccine was shown to be very efficacious in a nove

100 stabilize FiloRab1 (inactivated rabies-based Ebola vaccine), a candidate Ebola vaccine, and stored th

101 ted rabies-based Ebola vaccine), a candidate Ebola vaccine, and stored the vials at temperatures rang

102 hted the urgent need to develop an effective Ebola vaccine.

103 Although several leading candidate Ebola vaccines have been developed and advanced in clini

104 vaccine protection have been established for Ebola vaccines.

105 Funding for Ebola virus ($1.2 billion), Zika virus ($0.3 billion), i

106 as13a-based (SHERLOCK) diagnostics targeting Ebola virus (EBOV) and Lassa virus (LASV), with both flu

107 e family Filoviridae Because the filoviruses Ebola virus (EBOV) and Marburg virus (MARV) modulate hos

108 generation sequencing (mNGS) to detect Zaire Ebola virus (EBOV) and other potential pathogens from wh

109 Recent outbreaks of Ebola virus (EBOV) and severe acute respiratory syndrome

110 incorporates glycoproteins (GPs) from Zaire Ebola virus (EBOV) and Sudan Ebola virus (SUDV) and is d

111 say platform for ultrasensitive detection of Ebola virus (EBOV) antigens.

112 Marburg virus (MARV) and Ebola virus (EBOV) belong to the family Filoviridae.

113 Ebola virus (EBOV) causes epidemics with high mortality

114 Ebola virus (EBOV) continues to pose a significant threa

115 Ebola virus (EBOV) continues to pose significant threats

116 ed from 12 rhesus macaques that succumbed to Ebola virus (EBOV) disease from 5 to 8 days post exposur

117 Ebola virus (EBOV) disease has killed thousands of West

118 Ebola virus (EBOV) disease outbreaks, as well as the abi

119 evere and fatal illness epidemics such as of Ebola virus (EBOV) disease.

120 rkers (HCW) are more likely to be exposed to Ebola virus (EBOV) during an outbreak compared to people

121 Ebola virus (EBOV) entry into cells is mediated by its s

122 The Ebola virus (EBOV) envelope glycoprotein (GP) is a membr

123 Since the most recent outbreak, the Ebola virus (EBOV) epidemic remains one of the world's p

124 Ebola virus (EBOV) epidemics pose a major public health

125 ular stomatitis virus vaccine expressing the Ebola virus (EBOV) glycoprotein (GP) (rVSV-ZEBOV) was su

126 g vaccine efficacy against the highly lethal Ebola virus (EBOV) in humans is almost impossible due to

127 Ebola virus (EBOV) inclusion bodies (IBs) are cytoplasmi

128 al antibodies can mediate protection against Ebola virus (EBOV) infection through direct neutralizati

129 we perform a screen for genes essential for Ebola virus (EBOV) infection.

130 Given that the Ebola virus (EBOV) infects a wide array of organs and ce

131 Ebola virus (EBOV) is an enveloped, single-stranded RNA

132 g risk factors for household transmission of Ebola virus (EBOV) is important to guide preventive meas

133 Evidence from the 2013-2016 Ebola virus (EBOV) outbreak indicated that different gen

134 s have played a major role in propagation of Ebola virus (EBOV) outbreaks.

135 Evolution of antibody repertoire against the Ebola virus (EBOV) proteome was characterized in an acut

136 evelopment of Ebola virus disease.IMPORTANCE Ebola virus (EBOV) remains a high-priority pathogen sinc

137 Persistence of Ebola virus (EBOV) RNA in semen samples from survivors w

138 s of targeted versus nontargeted violence on Ebola virus (EBOV) transmission in Democratic Republic o

139 The Ebola virus (EBOV) VP40 matrix protein (eVP40) orchestra

140 for a single member of the Ebolavirus genus, Ebola virus (EBOV), and ineffective against outbreak-cau

141 ee classes of fusion proteins including HIV, Ebola virus (EBOV), influenza A virus (IAV) and Epstein

142 pathogens spread by close contact, including Ebola virus (EBOV), severe acute respiratory syndrome co

143 Ebola virus (EBOV), species Zaire ebolavirus, may persis

144 Several Ebola virus (EBOV)-specific and, more recently, pan-ebol

145 uman respiratory syncytial virus (HRSV), and Ebola virus (EBOV).

146 ported possible miRNA candidates produced by Ebola virus (EBOV).

147 vere and frequently lethal disease caused by Ebola virus (EBOV).

148 Recombinant vesicular stomatitis virus-Zaire Ebola virus (rVSV-ZEBOV) is the most advanced Ebola viru

149 recombinant vesicular stomatitis virus-Zaire Ebola virus (rVSV-ZEBOV) vaccine as an unlicensed emerge

150 GPs) from Zaire Ebola virus (EBOV) and Sudan Ebola virus (SUDV) and is designed to extend the breadth

151 >=37.5oC necessitating urgent screening for Ebola virus and a small number developed persistent arth

152 E Marburg virus (MARV) is a virus similar to Ebola virus and also causes a hemorrhagic disease which

153 Investments for high-threat pathogens (eg, Ebola virus and coronavirus) were often reactive and fol

154 enes (ISGs) against a biologically contained Ebola virus and identify several ISGs not previously kno

155 Entry inhibition was relatively robust for Ebola virus and influenza virus, modest for VSV, and mil

156 texposure treatments against the filoviruses Ebola virus and Marburg virus (MARV); however, the mecha

157 iruses, and previous studies with RdRps from Ebola virus and Middle East respiratory syndrome coronav

158 haemorrhagic fevers such as those caused by Ebola virus and other filoviruses.

159 o define positivity, we showed that specific Ebola virus antibodies are not widespread among NHPs.

160 (with a selectivity index of 303) and Makona Ebola virus at 13nM (with a selectivity index of 279).

161 Remdesivir inhibited Ituri Ebola virus at a 50% effective concentration (EC(50)) of

162 roles in infection prevention and control of Ebola virus by decontaminating high-touch environmental

163 Filoviruses such as Ebola virus continue to pose a substantial health risk t

164 ing antivirals.IMPORTANCE The development of Ebola virus countermeasures is challenged by our limited

165 ach of these factors, to predict the risk of Ebola virus disease (EVD) across time and space.

166 f viral hemorrhagic fevers (VHFs), including Ebola virus disease (EVD) and Lassa fever (LF), highligh

167 5, a 15-year-old boy received a diagnosis of Ebola virus disease (EVD) at the John F.

168 aper, we developed a compartmental model for Ebola virus disease (EVD) dynamics, which includes three

169 though several experimental therapeutics for Ebola virus disease (EVD) have been developed, the safet

170 Clinical sequelae of Ebola virus disease (EVD) have not been described more t

171 treatment center in Coyah, Guinea, confirmed Ebola virus disease (EVD) in 286 patients.

172 ne candidates.IMPORTANCE The pathogenesis of Ebola virus disease (EVD) in humans is complex, and the

173 rrently being used to combat the outbreak of Ebola virus disease (EVD) in the Democratic Republic of

174 orker presenting with a late reactivation of Ebola virus disease (EVD) in the United Kingdom.

175 The recent large outbreak of Ebola virus disease (EVD) in Western Africa resulted in

176 Ebola virus disease (EVD) is a severe and frequently let

177 The 2018 Ebola virus disease (EVD) outbreak in Equateur Province,

178 genomic information at the start of the 2018 Ebola virus disease (EVD) outbreak in North Kivu Provinc

179 ublic of the Congo (DRC) recorded its eighth Ebola virus disease (EVD) outbreak, approximately 3 year

180 ing the late phase of the large West-African Ebola virus disease (EVD) outbreak, the majority of pati

181 In this study, serum antibodies from Ebola virus disease (EVD) survivors from Sierra Leone we

182 ic, auditory, and visual complications among Ebola virus disease (EVD) survivors.

183 ic, auditory, and visual complications among Ebola Virus Disease (EVD) survivors; however, little is

184 Recent and ongoing outbreaks of Ebola virus disease (EVD) underscore the unpredictable n

185 evidence of subclinical and paucisymptomatic Ebola Virus Disease (EVD), the prevalence and associated

186 Zaire ebolavirus (EBOV) causes Ebola virus disease (EVD), which carries a fatality rate

187 ajor contributor to outcome in patients with Ebola virus disease (EVD), with high values leading to a

188 is a frequently recommended intervention in Ebola virus disease (EVD), yet its impact on patient out

189 preventive behaviours during an outbreak of Ebola virus disease (EVD).

190 Abs) is a promising therapeutic approach for Ebola virus disease (EVD).

191 dies are key components to prevent and treat Ebola virus disease (EVD).

192 ay persist in the semen of male survivors of Ebola Virus Disease (EVD).

193 ed, single-stranded RNA virus that can cause Ebola virus disease (EVD).

194 tality was high in people who recovered from Ebola virus disease and were discharged from Ebola treat

195 ene product could help prevent the spread of Ebola virus disease during outbreaks.

196 Following the Ebola virus disease epidemic in west Africa, there has b

197 onditions (based on the 2013-16 west African Ebola virus disease epidemic).

198 The 2014 West African outbreak of Ebola virus disease highlighted the urgent need to devel

199 symptoms observed in acute and convalescent Ebola virus disease in human patients.

200 The Ebola virus disease outbreak in west Africa has prompted

201 cs has been historically used to investigate Ebola virus disease outbreaks and how new technologies a

202 l failure in late deaths after recovery from Ebola virus disease should be investigated.

203 The most commonly reported symptom of post-Ebola virus disease syndrome in survivors is arthralgia,

204 ed to contact and follow-up all survivors of Ebola virus disease who were discharged from Ebola treat

205 protected non-human primates (NHPs) against Ebola virus disease.

206 the first licensed vaccine for prevention of Ebola virus disease.

207 ymptoms are the most common complications of Ebola virus disease.

208 tal organs contributes to the development of Ebola virus disease.IMPORTANCE Ebola virus (EBOV) remain

209 on of approved drugs to treat both Lassa and Ebola virus diseases.

210 markably potent small molecule inhibitors of Ebola virus entry.

211 or the deployment of the rVSVDeltaG-ZEBOV-GP Ebola virus envelope glycoprotein vaccine, available the

212 acute respiratory syndrome and west African Ebola virus epidemic, revealed serious shortcomings whic

213 The HAVCR1-NPC1 pathway, which Ebola virus exploits to infect cells(9), mediates HAV in

214 ensing strategy by using clinical samples of Ebola virus from patients.

215 e genetics system, we generated an authentic Ebola virus from the ongoing outbreak in Ituri and North

216 ogenetic analysis of representative complete Ebola virus genome sequences from previous outbreaks.

217 nt sequencing to produce two coding-complete Ebola virus genomes 5 days after declaration of the EVD

218 used target-enrichment sequencing to produce Ebola virus genomes from samples obtained in the 2018 Eq

219 2019;116:8535-8543) reported that Ebola virus genomes have variable 3' terminal nucleotide

220 Rapid Ebola virus genomic characterisation should be included

221 We designed novel synthetic anti-Ebola virus glycoprotein (EBOV-GP) DNA vaccines as a str

222 f normal immunocompetent mice.IMPORTANCE The Ebola virus glycoprotein contains a mucin-like domain wh

223 Studies using an Ebola virus glycoprotein fused to the Ag 85B epitope sho

224 For antibody testing, we used an Ebola virus glycoprotein IgG capture enzyme immunoassay

225 onstrated binding antibody responses against Ebola virus glycoprotein, and 87%-100% demonstrated neut

226 ely inhibit DC-SIGN-mediated augmentation of Ebola virus glycoprotein-driven cell entry (with IC(50)

227 Ebola virus GP vaccine with Matrix-M adjuvant is well to

228 A key viral factor in Ebola virus IB formation is the nucleoprotein, NP, which

229 s or serological testing was used to confirm Ebola virus infection in suspected cases.

230 A record number of people survived Ebola virus infection in the 2013-16 outbreak in west Af

231 btain a diverse experimental data set of the Ebola virus infection in vitro, and then make use of Bay

232 ement of the joints in acute or convalescent Ebola virus infection is not well characterized in human

233 ment was accelerated in response to the 2014 Ebola virus infection outbreak.

234 Our findings provide insights into Ebola virus infection that could be exploited for the de

235 Ebola virus infection was more widespread in this spillo

236 In human Ebola virus infection, clinical outcome is strongly asso

237 several ISGs not previously known to affect Ebola virus infection.

238 utic agents for the treatment and control of Ebola virus infections.

239 ically closest, with 98.73% homology, to the Ebola virus Mayinga variant isolated from the first DRC

240 Ebola virus modelling efforts have primarily focused on

241 nt from the Zaireebolavirus species, denoted Ebola virus Muyembe, was obtained using next-generation

242 analysis of whole-genome sequences from each Ebola virus outbreak suggests there are at least two Ebo

243 cumenting the beginnings of the west African Ebola virus outbreak, reveal important insight into tran

244 effective and practical therapies for future Ebola virus outbreaks.

245 han close contacts more than 2 decades after Ebola virus outbreaks.

246 ld provide a rapid-response treatment during Ebola virus outbreaks.

247 rodrug that has been clinically evaluated in Ebola virus patients and recently received emergency use

248 g variants in ongoing outbreaks, and also in Ebola virus patients undergoing remdesivir therapy.

249 ingle amino acid substitution, F548S, in the Ebola virus polymerase conferred low-level reduced susce

250 Homology modeling suggests that the Ebola virus polymerase F548 residue lies in the F-motif

251 Here, we wished to determine whether an anti-Ebola virus sdAb, that was cross-reactive within the Ebo

252 diagnostic assays for detection of the Ituri Ebola virus sequence.

253 Using Ebola virus sequences provided by organisations in DR Co

254 diagnostic assays detected Ituri and Makona Ebola virus sequences with similar sensitivities and eff

255 d assay for immunoglobulin G antibodies to 4 Ebola virus species.

256 sion dynamics and risk factors that underpin Ebola virus spillover events.

257 rus outbreak suggests there are at least two Ebola virus strains in DR Congo, which have independentl

258 We identified nine amino acid changes in the Ebola virus surface glycoprotein, of which one resulted

259 e utility of FDA-ARGOS reference genomes for Ebola virus target sequence comparison as part of a comp

260 and HBV, while all isoforms equally inhibit Ebola virus transcription and replication.

261 profile of remdesivir by serially passaging Ebola virus under remdesivir selection; we generated lin

262 bola virus (rVSV-ZEBOV) is the most advanced Ebola virus vaccine candidate and is currently being use

263 idered in rational design strategies for new Ebola virus vaccine candidates.IMPORTANCE The pathogenes

264 issemination of the causative agent, a novel Ebola virus variant closely related to the initial Mayin

265 using genomics to rapidly characterise a new Ebola virus variant within the timeframe of an outbreak.

266 evealed a distinct cluster, confirming a new Ebola virus variant, for which we propose the name "Tumb

267 to have evolved at a slower rate than other Ebola virus variants (0.69 x 10(-3) substitutions per si

268 ence in other analogous proteins such as the Ebola virus VP35 evinces a broader purpose for LC8 in re

269 late from this outbreak, a recombinant Ituri Ebola virus was compared with a similarly engineered Mak

270 nal antibodies 2G4 and 4G7 neutralised Ituri Ebola virus with a mean EC(50) of 0.24 mug/mL and 0.48 m

271 ) of 0.24 mug/mL and 0.48 mug/mL, and Makona Ebola virus with a mean EC(50) of 0.45 mug/mL and 0.2 mu

272 egrees C, necessitating urgent screening for Ebola virus, and a small number developed persistent art

273 he past 50 years, several viruses, including Ebola virus, Marburg virus, Nipah virus, Hendra virus, s

274 thal disease and lack targeted therapeutics: Ebola virus, Sudan virus and Bundibugyo virus.

275 ptions of many viral infections, but for the Ebola virus, which requires biosafety level 4 facilities

276 ort the development of a bivalent, spherical Ebola virus-like particle (VLP) vaccine that incorporate

277 ferent microbicidal actives for inactivating Ebola virus-Makona strain (EBOV/Mak) on stainless-steel

278 primer site binding mismatches in the Ituri Ebola virus.

279 viruses, such as measles, rabies virus, and Ebola virus.

280 ety of negative-sense RNA viruses, including Ebola virus.

281 o develop a therapeutic mAb cocktail against Ebola virus.

282 A time course of infection study with Ebola virus/Kikwit found that the large joint synovium b

283 le (knee) is a target for acute infection by Ebola virus/Kikwit, Ebola virus/Makona-C05, and Marburg

284 t for acute infection by Ebola virus/Kikwit, Ebola virus/Makona-C05, and Marburg virus/Angola in the

285 lder, and hip are a target for mouse-adapted Ebola virus/Yambuku-Mayinga infection during acute disea

286 t neutralized all four pathogenic species of Ebola viruses and elicited antibody-dependent cell-media

287 cellular immune responses against pathogenic Ebola viruses and support further evaluation of this app

288 To relate this virus to other Ebola viruses in DR Congo, we did a phylogenetic analysi

289 imal reservoir and understand the ecology of Ebola viruses to inform disease control.

290 emerging viral pathogens, including HIV and Ebola viruses, are most prevalent in regions of the worl

291 en immune responses against known pathogenic Ebola viruses.

292 y extend protective immune responses against Ebola viruses.

293 se results demonstrate that a novel bivalent Ebola VLP vaccine elicits strong humoral and cellular im

294 Immunization of rabbits with bivalent Ebola VLPs produced antibodies that neutralized all four

295 ases with longer incubation periods, such as Ebola, where infected individuals can travel farther bef

296 didate chimpanzee adenovirus type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) and boosted with modif

297 binant chimpanzee adenovirus type 3 vectored Ebola Zaire vaccine (ChAd3-EBO-Z) followed by MVA-EBO-Z.

298 ctor modified vaccinia Ankara virus vectored Ebola Zaire vaccine (MVA-EBO-Z), manufactured rapidly on

299 Z) and boosted with modified vaccinia Ankara Ebola Zaire-vectored (MVA-EBO-Z) vaccine.

300 y to enveloped viruses, including influenza, Ebola, Zika, Nipah, chikungunya, Una, Mayaro, Dugbe, and